Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer

• Published in: American journal of obstetrics and gynecology Vol. 225; no. 1; pp. 68.e1 - 68.e11
• Main Authors: Harrison, Ross F., Fu, Shuangshuang, Sun, Charlotte C., Zhao, Hui, Lu, Karen H., Giordano, Sharon H., Meyer, Larissa A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2021
• Subjects: costs of care; financial burden; financial hardship; financial toxicity; gynecologic cancer; health services research; healthcare costs; out-of-pocket costs; ovarian cancer; PARP inhibitor; health services research; out-of-pocket costs; financial toxicity; ovarian cancer; financial hardship; PARP inhibitor; gynecologic cancer; costs of care; healthcare costs; financial burden

More patients with ovarian cancer are being treated with poly(adenosine diphosphate-ribose) polymerase inhibitors because regulatory agencies have granted these drugs new approvals for a variety of treatment indications. However, poly(adenosine diphosphate-ribose) polymerase inhibitors are expensive...